Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Oncobiologics, Inc. (OTLK : NSDQ)

• Company Description    Outlook Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focuses on developing ONS-5010 which is a proprietary ophthalmic bevacizumab product candidate for the treatment of wet age related macular degeneration which is in clinical stage. Outlook Therapeutics Inc., formerly known as Oncobiologics Inc., is based in Cranbury, United States. Number of Employees: 17

• Price / Volume Information    Yesterday's Closing Price: $1.58 Daily Weekly Monthly 20 Day Moving Average: 4,894,516 shares Shares Outstanding: 64.11 (millions) Market Capitalization: $101.30 (millions) Beta: 0.17 52 Week High: $3.39 52 Week Low: $0.60 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -23.30% -23.17% 12 Week 28.45% 26.38% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 111 S. WOOD AVENUE UNIT #100 - ISELIN,NJ 08852 USA ph: 609-619-3990 fax: - otlk@jtcir.com http://www.outlooktherapeutics.com

• General Corporate Information    Officers Robert C. Jahr - Chief Executive Officer Faisal G. Sukhtian - Chairman Lawrence A. Kenyon - Chief Financial Officer Kurt J. Hilzinger - Director Julia A. Haller - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 69012T305 SIC: 2836 Fiscal Year Fiscal Year End: September Last Reported Quarter: 09/01/25 Next Expected EPS Date: 02/13/26 Share - Related Items Shares Outstanding: 64.11 Most Recent Split Date: 3.00 (0.05:1) Beta: 0.17 Market Capitalization: $101.30 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.17 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.77 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 02/13/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 71.43% vs. Previous Quarter: 50.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 12/31/25 - - 09/30/25 - - 06/30/25 - - ROA 12/31/25 - - 09/30/25 - -340.05 06/30/25 - -332.30 Current Ratio 12/31/25 - - 09/30/25 - 0.38 06/30/25 - 0.67 Quick Ratio 12/31/25 - - 09/30/25 - 0.31 06/30/25 - 0.54 Operating Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Net Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Pre-Tax Margin 12/31/25 - - 09/30/25 - -4,524.54 06/30/25 - -2,886.25 Book Value 12/31/25 - - 09/30/25 - -0.60 06/30/25 - -0.86 Inventory Turnover 12/31/25 - - 09/30/25 - 0.38 06/30/25 - 0.16 Debt-to-Equity 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Capital 12/31/25 - - 09/30/25 - - 06/30/25 - -

Powered by Zacks Investment Research ©